| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| EXAGEN INC. | CFO and Corporate Secretary | Common Stock | 244K | $466K | $1.91 | Mar 4, 2024 | Direct |
| FATE THERAPEUTICS INC | Chief Financial Officer | Common Stock | 75K | $94.5K | $1.26 | Oct 20, 2025 | Direct |
| FATE THERAPEUTICS INC | Chief Financial Officer | Stock Option (Right to Buy) | 375K | Oct 20, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| FATE | FATE THERAPEUTICS INC | Oct 20, 2025 | 2 | $0 | 4 | Oct 21, 2025 | Chief Financial Officer |
| FATE | FATE THERAPEUTICS INC | Oct 20, 2025 | 0 | $0 | 3 | Oct 21, 2025 | Chief Financial Officer |
| XGN | EXAGEN INC. | Mar 4, 2024 | 2 | -$24.4K | 4 | Mar 6, 2024 | CFO and Corporate Secretary |
| XGN | EXAGEN INC. | Feb 20, 2024 | 1 | $0 | 4 | Feb 22, 2024 | CFO and Corporate Secretary |
| XGN | EXAGEN INC. | Feb 6, 2024 | 1 | -$13.1K | 4 | Feb 8, 2024 | CFO and Corporate Secretary |
| XGN | EXAGEN INC. | Mar 2, 2023 | 1 | -$8.43K | 4 | Mar 3, 2023 | CFO and Corporate Secretary |
| XGN | EXAGEN INC. | Feb 27, 2023 | 1 | $0 | 4 | Mar 1, 2023 | CFO and Corporate Secretary |
| XGN | EXAGEN INC. | Feb 8, 2023 | 1 | -$15.7K | 4 | Feb 10, 2023 | CFO and Corporate Secretary |
| XGN | EXAGEN INC. | Mar 1, 2022 | 1 | -$23.1K | 4 | Mar 2, 2022 | CFO and Corporate Secretary |
| XGN | EXAGEN INC. | Feb 4, 2022 | 1 | $0 | 4 | Feb 8, 2022 | CFO and Corporate Secretary |